A5086816424- T-cell and Retrovirus Studies
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Vascular Anomalies and Treatments
- Reconstructive Surgery and Microvascular Techniques
- Wound Healing and Treatments
- Surgical site infection prevention
- Cancer-related gene regulation
- Prenatal Screening and Diagnostics
Jiangsu Hengrui Medicine (China)
2024
Hainan General Hospital
2022
Hainan Medical University
2020-2022
Sichuan University
2013
Patients with peripheral T-cell lymphomas (PTCL) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and prognosis is extremely poor. SHR2554 an oral inhibitor against EZH2, rational therapeutic target for lymphomas.
<div>AbstractPurpose:<p>Patients with peripheral T-cell lymphomas (PTCL) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and prognosis is extremely poor. SHR2554 an oral inhibitor against EZH2, rational therapeutic target for lymphomas.</p>Patients Methods:<p>This was multicenter, two-part, phase I study r/r mature lymphoid neoplasms. In part I, 350 mg twice daily established as recommended II dose (RP2D) based on...
<p>Supplementary Figure S1. Progression-free survival by lymphoma subtype.</p>
<p>Supplementary Method. Inclusion and exclusion criteria of the dose-escalation, dose-expansion, clinical expansion part I this phase 1 study.</p>
<div>AbstractPurpose:<p>Patients with peripheral T-cell lymphomas (PTCL) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and prognosis is extremely poor. SHR2554 an oral inhibitor against EZH2, rational therapeutic target for lymphomas.</p>Patients Methods:<p>This was multicenter, two-part, phase I study r/r mature lymphoid neoplasms. In part I, 350 mg twice daily established as recommended II dose (RP2D) based on...
<p>Supplementary Method. Inclusion and exclusion criteria of the dose-escalation, dose-expansion, clinical expansion part I this phase 1 study.</p>
<p>Supplementary Figure S1. Progression-free survival by lymphoma subtype.</p>
Abstract Background: Thalassemia is one of the most prevalent inherited single gene diseases. Prevention β-thalassemia through prenatal diagnosis effective and direct approach to control spread this life-threatening disease. This study aims determine α-thalassemia in 3049 families among eighteen regions Hainan Province using molecular diagnosis. Methods: enrolled a total couples their fetuses at The First Affiliated Hospital Medical University from January 2004 March 2020. Genomic DNA was...
To investigate the influence factors of poor efficacy after flap repair operation in patients with pressure ulcers.